Moderna’s Cancer Vaccine Makes Waves | Denver News

Moderna’s stock surged as it unveiled early data on its groundbreaking mRNA cancer vaccine, Intismeran—designed to target a patient’s unique tumor mutations. When paired with Merck’s Keytruda, the combo showed stronger results in melanoma patients, delaying cancer recurrence or spread. While full survival stats are pending, this could mark a revolutionary leap in personalized oncology, proving mRNA tech’s power beyond infectious disease vaccines. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/05bd3a3cb313b625